![Charles Wu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charles Wu
Direttore Tecnico/Scientifico/R&S presso Beijing Continent Pharmaceutical Co., Ltd.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Charles Wu is currently the Chief Technology Officer at Beijing Continent Pharmaceutical Co., Ltd.
He previously served as the Chief Executive Officer & Director at Gyre Therapeutics, Inc. from 2023 to 2024.
Dr. Wu holds an MBA from Tulane University, a doctorate from the University of Maryland, and an undergraduate degree from the University of Science & Technology of China.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
-.--% | 19/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Charles Wu
Società | Posizione | Inizio |
---|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Direttore Tecnico/Scientifico/R&S | 01/01/2020 |
Precedenti posizioni note di Charles Wu
Società | Posizione | Fine |
---|
Formazione di Charles Wu
University of Science & Technology of China | Undergraduate Degree |
University of Maryland | Doctorate Degree |
Tulane University (Louisiana) | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Beijing Continent Pharmaceutical Co., Ltd.
![]() Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Borsa valori
- Insiders
- Charles Wu